Patient-reported outcomes of NRG Oncology/RTOG 0232: a phase III study comparing combined external beam radiation and transperineal interstitial permanent brachytherapy with brachytherapy alone in intermediate risk prostate cancer.

**Presenter:** Deborah W. Bruner, PhD  
**Discussant:** Ronald C. Chen, MD

Receipt of adjuvant endometrial cancer treatment according to race: an NRG Oncology/Gynecologic Oncology Group 210 Study.

**Presenter:** Ashley S. Felix, PhD  
**Discussant:** William (Rusty) Robinson, MD

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally-advanced rectal cancer (LARC): first experimental arm (EA) initial results.

**Presenter:** Thomas J. George, MD  
**Discussant:** Steven H. Lin, MD

Initial reporting of NRG-LU001 (NCT02186847), randomized phase II trial of concurrent chemoradiotherapy (CRT) +/- metformin HCL in locally advanced non-small cell lung cancer (NSCLC).

**Presenter:** Theodoros Tsakiridis, MD  
**Discussant:** Adam P. Dicker, MD

Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

**Presenter:** Joan L. Walker, MD  
**Discussant:** Ursula A. Matulonis, MD

Patient-reported outcomes (PROs) in NRG Oncology/NSABP B-39/RTOG 0413: a randomized phase III study of conventional whole breast irradiation (WBI) v partial breast irradiation (PBI) in stage 0, I, or II breast cancer.

**Presenter:** Patricia A. Ganz, MD

Evolutionary action score of TP53 analysis in pathologically high-risk HPV-negative head and neck cancer from a phase II clinical trial: NRG Oncology RTOG 0234.

**Presenter:** Chieko Michikawa, DDS, PhD